🔥JCOG0802/WJOG4607L: Segmentectomy vs lobectomy in pts with pathologically invasive features
🆙 @JTOonline
🎯Segmentx: OS HR 0.657 (CI 0.401-1.077), local relapse HR 2.23 (CI 1.334–3.741)
🎙Dr. Shinya Katsumata
#LCSM@OncoAlert@Larvol@JCOG_official
https://t.co/0VVjXuxq8M
The entire @Sunnybrook spine #SBRT team has come together to share 17 years of research and clinical observations in this review for @NatRevClinOncol. We are a true multidisciplinary team that have had a singular focus to develop the technique and evidence https://t.co/IHALJ97ZCa
STAMPEDE post-hoc (5 phase 3 trials, n=7129): on-treatment PSA predicts OS in prostate cancer. PSA ≤0.2 ng/mL at any timepoint = favorable, with week 24 strongest.
👉Combine PSA + metastatic volume/nodal status to refine prognosis & guide trials.
‼️Next? Could we use PSA response to escalate or de-escalate of doublet/triplet?
@OncoAlert@APCCC_Lugano@TheLancetOncol
https://t.co/nVABjZ8atT
1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.
MRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)—PART I primary staging.https://t.co/80DS0kJMkh
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. https://t.co/3SKc65HRwt